Protection against systemic infections with various<i>Candida</i>species elicited by vaccination with<i>Candida albicans</i>ribosomes

Segal, Esther; Nussbaum, Sarah; Barr-Nea, L.

doi:10.1080/00362178585380401

Cited by 10 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, ribosomal fractions were also used to try to induce protection against candidemia. Studies documented that it was possible to induce protection by immunization with C. albicans ribosomes, not only against heterologous C. albicans strains, with 30-78% of survival, but also cross protection against C. tropicalis isolates, with 57 to 64% of survival rate from a systemically administered lethal infection [85]. Ribosomal vaccine was also exploited in experimentally induced cell-mediated immunocompromised mice, resulting in a survival rate that reached 76% [86].…”

Section: Ribosomal Vaccinesmentioning

confidence: 99%

Vaccination Against Fungal Diseases: Lessons from Candida albicans

Sampaio

Pais

2017

Immunogenetics of Fungal Diseases

View full text Add to dashboard Cite

The advances in medicine have achieved great benefits by improving or even eliminating various debilitating diseases or malignancies, expanding life expectancy. However, it has also originated the development of a compromised population susceptible to opportunistic diseases. A global major concern is the emergence and spread of life-threatening invasive infections in immunocompromised patients, in which the opportunistic fungal infections have greatly increased in the last decades. The high mortality rates associated with these infections, which remain as high as 40%, are due to the limited therapeutic options and the emergence of drug resistant fungi, but also due to the lack of efficient early diagnosis. Consequently, these facts led to the opinion that new approaches are needed to improve the outcome of these patients, such as immunopreventive strategies that could even be combined with standard antifungal treatment. In view of the proven effectiveness of various antibacterial and antiviral vaccines in preventing the respective diseases, several works have been developed to induce protective immunity against fungal infections as well. The better understanding of how the immune system works against fungal pathogens has made possible to explore immunomodulatory strategies that can protect both immunocompetent and immunocompromised hosts and generate memory. Recently, two fungal vaccines against Candida have advanced through clinical trials. However, there are still many challenges in the development of an efficient vaccine against invasive fungal infections. We will provide an update on the progress made in immunization against fungal infections, reviewing host-fungi interactions, antigens and adjuvants exploited in vaccine strategies, and discuss concerns that need to be overcome to further advance in the area of fungal vaccines.

show abstract

Section: Ribosomal Vaccinesmentioning

confidence: 99%

Vaccination Against Fungal Diseases: Lessons from Candida albicans

Sampaio

Pais

2017

Immunogenetics of Fungal Diseases

View full text Add to dashboard Cite

show abstract

“…It is the type species strain and was originally isolated from a skin disorder (19). The strain was characterized as serotype A (33) and was extensively used in previous studies in our laboratory (31,32). Other C. albicans isolates were used for comparative electrophoretic karyotyping.…”

Section: Methodsmentioning

confidence: 99%

Isolation of the Candida albicans histidinol dehydrogenase (HIS4) gene and characterization of a histidine auxotroph

et al. 1990

View full text Add to dashboard Cite

Genetic studies were done with Candida albicans CBS 562. Various auxotrophs were isolated following mutagenesis with N-methyl-N'-nitro-N-nitrosoguanidine. SAG5 (his4C), a stable histidine auxotroph defective in histidinol dehydrogenase activity, was characterized and chosen for further molecular studies. Therefore, the C. albicans HIS4 gene was isolated. The gene was obtained from a genomic library of the wild-type strain, which was constructed in plasmid YEp24. The HIS4 gene was isolated by transformation of a Saccharomyces cerevisiae strain that carried a his4 mutation. The isolated C. albicans HIS4 gene complemented S. cerevisiae his4A, his4B, his4C, and his4ABC mutant strains, which indicates that the clone contains the entire HIS4 gene. The gene was isolated on plasmid pSTC7, whose physical map was constructed with BamHI, SalI, and EcoRV restriction endonucleases, locating the HIS4 gene on a 14-kilobase-pair DNA fragment. Hybridization experiments with HIS4 and C. albicans genomic DNA showed correspondence between the restriction patterns of the gene with that of the chromosomal DNA, indicating that the gene originates from C. albicans and appears in a single copy. Chromosomes of C. albicans CBS562 and four other strains were resolved by orthogonal-field alteration gel electrophoresis. The electrokaryotyping results showed heterogeneity in chromosomal sizes. The electrokaryotyping of CBS 562 showed a resolution of six chromosomal bands, three of which seemed to be doublets. The C. albicans HIS4 gene was located on the largest resolvable chromosome in all of the strains.

show abstract

Testing Antifungal Vaccines in an Animal Model of Invasive Candidiasis and in Human Mucosal Candidiasis

Segal

2017

Methods in Molecular Biology

View full text Add to dashboard Cite

The following article will concentrate on the NDV-3 anti-Candida and Staphylococcus vaccine. The vaccine is composed of the N-terminal portion of the Candida albicans agglutinin-like sequence 3 protein (Als3p) and aluminum hydroxide as adjuvant. The vaccine conferred protection to mice against experimental vaginal, oral, and intravenous challenge with C. albicans. Due to the sequence and structural homology of the Als3p with Staphylococcus aureus surface proteins, the vaccine also protected against experimental skin and IV infection with S. aureus. The vaccine has reached the stage of human trials: phase 1 clinical studies have shown that the vaccine is safe and immunogenic. The latest brief conference abstract reports of vaccination in women suffering from recurrent vaginal candidiasis, indicating that the recurrence rates were lower in the women receiving the vaccine.

show abstract

Protection against systemic infections with variousCandidaspecies elicited by vaccination withCandida albicansribosomes

Cited by 10 publications

References 18 publications

Vaccination Against Fungal Diseases: Lessons from Candida albicans

Vaccination Against Fungal Diseases: Lessons from Candida albicans

Isolation of the Candida albicans histidinol dehydrogenase (HIS4) gene and characterization of a histidine auxotroph

Testing Antifungal Vaccines in an Animal Model of Invasive Candidiasis and in Human Mucosal Candidiasis

Contact Info

Product

Resources

About